Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In situ malignant melanoma on nevus spilus in an elderly patient.
Corradin MT, Giulioni E, Fiorentino R, Santeufemia DA, Re GL, Vettorello A. Corradin MT, et al. Among authors: re gl. Acta Dermatovenerol Alp Pannonica Adriat. 2014 Mar;23(1):17-9. Acta Dermatovenerol Alp Pannonica Adriat. 2014. PMID: 24638867 Free article.
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
Buti S, Lazzarelli S, Chiesa MD, Simonelli C, Re GL, Lheshi A, Simon S, Mattioli R, Caminiti C, Mazza G, Donini M, Passalacqua R; GOIRC (Italian Oncology Group for Clinical Research). Buti S, et al. Among authors: re gl. J Immunother. 2010 Sep;33(7):735-41. doi: 10.1097/CJI.0b013e3181eb8289. J Immunother. 2010. PMID: 20664353 Clinical Trial.
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E. Porta C, et al. Among authors: re gl. BJU Int. 2011 Oct;108(8 Pt 2):E250-7. doi: 10.1111/j.1464-410X.2011.10186.x. Epub 2011 May 23. BJU Int. 2011. PMID: 21599821
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment.
Giordano G, Milella M, Landriscina M, Bergamo F, Tirino G, Santaniello A, Zaniboni A, Vasile E, De Vita F, Re GL, Vaccaro V, Giommoni E, Natale D, Conca R, Santini D, Maiorino L, Sanna G, Ricci V, Iop A, Montesarchio V, Procaccio L, Noventa S, Bianco R, Febbraro A, Lonardi S, Tortora G, Sperduti I, Melisi D. Giordano G, et al. Among authors: re gl. Cancer Med. 2024 Jun;13(12):e7345. doi: 10.1002/cam4.7345. Cancer Med. 2024. PMID: 38924262 Free PMC article.
Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L, Fiorentini G, Guida M, Michiara M, Freschi A, Aitini E, Ballardini M, Bichisao E, Ridolfi R; Italian Melanoma Intergroup. Ridolfi L, et al. Melanoma Res. 2009 Apr;19(2):100-5. doi: 10.1097/CMR.0b013e328328f7ec. Melanoma Res. 2009. PMID: 19262411 Clinical Trial.
29 results